Clinically available since 1995* • More than 100,000 treatments performed • Reproducible clinical benefits
More than 200 scientific papers and peer reviewed articles available
PMX is indicated for patients with Sepsis and endotoxemia or suspected gram negative infection.
Recent data suggests that the best patients for PMX therapy have the following characteristics:
• Septic shock requiring continuous vasopressor support
• Multiple Organ Dysfunction (MODS>9)
The following graphic describes the decision making process that should be followed to prescribe
PMX hemoperfusion therapy.
The only double blinded, randomized trial of PMX (The EUPHRATES Trial) demonstrated that PMX cartridge therapy increased both ventilator free and renal replacement therapy free days. Additionally, patients who received PMX therapy had a greater increase in mean arterial pressure as well as a decreased requirement for vasopressors. Further, a decrease in 28-day mortality was observed for PMX treated patients as compared to patients who did not receive PMX. A group of patients with baseline EAA™ results of ≥0.60 and <0.90 at randomization, treated with PMX, had a 28 day mortality of 26% as compared to 37% in patients who did not receive PMX (p<0.05, n=194). In the same population, patients who received PMX had a 90 day mortality of 30% as compared to 41% in patients who did not receive PMX (p=<0.04, n=194).
135 The West Mall, Unit 2 • Toronto, Ontario • M9C 1C2 Canada
Tel: 1.416.626.3233 • Toll Free: 1.888.426.4264 • Fax: 1.416.626.7383